BDTX
Black Diamond Therapeutics, Inc.
NasdaqGS Healthcare United States
1,94 $US
+2.65% today
-22.09% YTD · -50.51% 1Y
2
Insider transactions
SEC Form 4 · AMF · BaFin — rolling 90 days
15
Hedge funds tracked
Latest available SEC 13F filings
62
/ 100
STRONG

Analysis Black Diamond Therapeutics, Inc. (BDTX) — Kairos Score 62/100

Composite score aggregating 8 smart money dimensions: insiders (SEC/AMF/BaFin), hedge funds, politicians & gurus, price momentum, valuation, analyst consensus, financial health, earnings momentum. The higher the score, the more favorable the institutional signals consensus.

💡 Detailed breakdown (the 8 sub-scores) available in the Premium dashboard.

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Key info

👔
CEO
Dr. Mark A. Velleca M.D., Ph.D.
📍
HQ
245 First Street, 18th Floor, Cambridge, MA, 02142, United States
👥
Employees
21
💰
Market cap
108 587 580,00 $US
💸
Dividend yield
—

🕴️ Insider activity (90 days)

2 transactions — 0 buys and 0 sales reported by Black Diamond Therapeutics, Inc. executives.

RP
Raman Prakash
2026-09-18
Other
BA
Behbahani Ali
2026-09-18
Other

🏦 Hedge Funds

15 institutional funds report a position on BDTX in their latest SEC quarterly filing.

BlackRock, Inc.
VANGUARD GROUP INC
VANGUARD CAPITAL MANAGEMENT LLC
RENAISSANCE TECHNOLOGIES LLC
DIMENSIONAL FUND ADVISORS LP

📰 Recent news

15 recent articles on BDTX.

🧠 What makes Kairos Insider

Beyond raw data, we aggregate and score every smart money signal to give you a unique view.

🧠

Kairos Score 0-100

8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.

🎯

Insider Clusters

Detection of clustered purchases or sales by several executives in the same stock.

🏦

13F Hedge Funds

Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.

📈

ETF Rotations

NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.

🔥

Google Trends

Spot marked changes in search interest around the stocks being followed.

📧

Email alerts

Create your watchlist and receive a brief of events affecting your tickers.

Companies in the same sector as Black Diamond Therapeutics, Inc.

Official sources · Public data · SEC EDGAR — Form 4 & 13F · AMF — Executive filings · BaFin — Directors' Dealings · Yahoo Finance · Alpha Vantage

🔓 Unlock the full analysis

This public page only shows a preview. The full analysis of BDTX on the Kairos Insider dashboard includes:

✅ Full Kairos Score (8-axis radar + synthesis)
✅ History of all 2 insider transactions over 90 days
✅ All 15 detected institutional funds
✅ Thematic ETFs (ARK, BUZZ, NANC, GOP, JEPI…)
✅ Hot Stocks Google Trends
✅ Available history: AUM + rotations
✅ Fundamentals (P/E, PEG, EV/EBITDA, ROE…)
✅ Financial health (Altman Z, Piotroski F)
✅ Sector peers + recent earnings
See full analysis →
Analyze other tickers for free →

Free signup · Pro €19/month or €190/year